• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23982 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Intraoperative Radiation Therapy for Breast Cancer]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of phalloplasty as a masculinizing genital surgery: a systematic review]
2025     NIHR Health Technology Assessment programme Protocol for DexEnceph: a randomised controlled trial of dexamethasone therapy in adults with herpes simplex virus encephalitis
2024     Ontario Health Peripheral nerve stimulation for chronic neuropathic pain
2024     Ontario Health Interferon-gamma release assay testing for latent tuberculosis infection
2024     Ontario Health Single-exposure, dual-energy subtraction flat panel x-ray detectors
2024     Ontario Health Plasma-based comprehensive genomic profiling DNA assays for non-small cell lung cancer
2024     Canary Health Service [Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnea]
2024     Canary Health Service [Assessment of body composition using electrical bioimpedance for the evaluation of overweight and obesity in primary care]
2024     Canary Health Service [Molecular urine-based biomarkers for the diagnosis of urothelial carcinoma]
2024     Andalusian Health Technology Assessment Area (AETSA) [Efficacy of non-invasive locoregional hyperthermia as adjuvant to radio/chemotherapy in oncological indications - systematic review and meta-analysis]
2024     Andalusian Health Technology Assessment Area (AETSA) [Safety and efficacy of integrated robotic systems for coronary procedures]
2024     Agency for Care Effectiveness (ACE) Axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy
2024     Agency for Care Effectiveness (ACE) Tisagenlecleucel for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2024     Agency for Care Effectiveness (ACE) Recombinant zoster vaccine for the prevention of herpes zoster and post-herpetic neuralgia
2024     Agency for Care Effectiveness (ACE) Nirmatrelvir and ritonavir combination for treating mild-to-moderate COVID-19
2024     Agency for Care Effectiveness (ACE) Cabotegravir with rilpivirine for treating human immunodeficiency virus type 1 (HIV-1) infection
2024     Agency for Care Effectiveness (ACE) Selexipag for treating pulmonary arterial hypertension
2024     Agency for Care Effectiveness (ACE) Trastuzumab deruxtecan for HER2-low unresectable and or metastatic breast cancer after at least one prior line of chemotherapy
2024     Agency for Care Effectiveness (ACE) Tisagenlecleucel for relapsed or refractory B-cell acute lymphoblastic leukaemia
2024     Agency for Care Effectiveness (ACE) Burosumab for treating X-linked hypophosphataemia
2024     Agency for Care Effectiveness (ACE) Calcitonin gene-related peptide monoclonal antibodies for prophylaxis of migraine
2024     Agency for Care Effectiveness (ACE) Enzyme replacement therapies for Fabry disease
2024     Agency for Care Effectiveness (ACE) Nusinersen and risdiplam for treating spinal muscular atrophy
2024     Agency for Care Effectiveness (ACE) Ruxolitinib for treating graft-versus-host disease
2024     Agency for Care Effectiveness (ACE) Tolvaptan for treating autosomal dominant polycystic kidney disease
2024     National Institute for Health and Care Excellence (NICE) Sebelipase alfa for treating Wolman disease. NICE highly specialised technologies guidance 30
2024     National Institute for Health and Care Excellence (NICE) Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome. NICE highly specialised technologies guidance 31
2024     Agency for Care Effectiveness (ACE) Cervical artificial disc replacement for treatment of patients with cervical disc degenerative disease
2024     Agency for Care Effectiveness (ACE) Continuous glucose monitoring systems for children and adults with type 1 diabetes mellitus
2024     Agency for Care Effectiveness (ACE) Lumbar artificial disc replacement for treatment of patients with lumbar disc degenerative disease
2024     Agency for Care Effectiveness (ACE) Radiolucent fixation rods & screws for patients with primary and metastatic spinal tumours
2024     Agency for Care Effectiveness (ACE) Tricuspid transcatheter edge-to-edge repair system for symptomatic severe tricuspid regurgitation
2024     Canary Health Service [Cost-effectiveness of neonatal screening for spinal muscular atrophy and severe combined immunodeficiency]
2024     Canary Health Service [Psychological interventions in paediatric population eligible for palliative care and their family]
2024     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [The mental health day hospital: drawing on the literature to define the service offer and enhance practice]
2024     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Mechanisms and interventions to prevent intrusive wandering by residents with neurocognitive disorders in long-term care facilities]
2024     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Considerations related to risk treatment in the context of home care for older adults and courses of action to support care providers]
2024     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Physiotherapy interventions for adult with persistent symptoms following mild traumatic brain injury]
2024     Agency for Care Effectiveness (ACE) FEops HEARTguide for procedure planning in patients needing transcatheter left atrial appendage occlusion (LAAO) device
2024     Agency for Care Effectiveness (ACE) Oxevision for vision-based patient monitoring and management in mental health wards
2024     Agency for Care Effectiveness (ACE) KidneyIntelX for patients with diabetic kidney disease
2024     Agency for Care Effectiveness (ACE) Organ Care System (OCS) Heart System for heart transplantation of marginal brain-death donor hearts or circulatory-death donor hearts
2024     Agency for Care Effectiveness (ACE) RelieVRx for the treatment of chronic lower back pain
2024     Agency for Care Effectiveness (ACE) Canvas Dx to aid the diagnosis of autism spectrum disorder
2024     Agency for Care Effectiveness (ACE) CavaClear for patients with difficult inferior vena cava filters (IVCFs) retrieval who have failed a previous retrieval method
2024     Agency for Care Effectiveness (ACE) Nerivio for the acute and preventive treatment of migraine
2024     Agency for Care Effectiveness (ACE) Transcutaneous afferent patterned stimulation for patients with essential tremor or Parkinsons Disease
2024     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Point-of-care ultrasound for the evaluation of pulmonary volume overload in an outpatient setting]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Chronic graft-versus-host disease; assessment according to §35a Social Code Book (SGB) V; search for disease registries]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection - iptacopan (paroxysmal nocturnal haemoglobinuria)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection - epcoritamab (relapsed or refractory follicular lymphoma)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection – Odronextamab (relapsed or refractory follicular lymphoma)]
2024     Canary Health Service [Safety and efficacy of the use of compression garments in the treatment of lipedema]
2024     NIHR Health Services and Delivery Research programme Routine outcomes to investigate differences between ethnic minorities and white British people presenting to emergency services for injury: the stakeholder consultation
2024     Austrian Institute for Health Technology Assessment (AIHTA) Telehealth in diabetes – EU mapping and systematic evaluation of organisational aspects
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Botulinum toxin in dystonia, dyspareunia, and strabismus]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Threshold values in health economic evaluations and decision-making
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Strategies for reducing weight stigmatisation towards people with overweight or obesity in the healthcare system]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Artificial Intelligence in health care with a focus on hospitals: methodological considerations for health technology assessment: a scoping review
2024     Austrian Institute for Health Technology Assessment (AIHTA) Oncological breast cancer care in selected European countries: cross-sectoral cancer care models
2024     Austrian Institute for Health Technology Assessment (AIHTA) Mental health screening of adults in primary care
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Massive parallel sequencing – technologies for high-throughput analysis of genetic-genomic data sets]
2024     Gesundheit Osterreich GmbH (GOeG) [Long-term effectiveness of early interventions for children and adolescents with psychological stress]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with heart failure]
2024     Scottish Health Technologies Group (SHTG) Digital fracture liaison service
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Rigid-platform (TEM/ TEO) or flexible-platform (TAMIS) endoscopic transanal surgery for the treatment of rectal lesions]
2024     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Proton therapy in cancer treatment: evaluation of safety, efficacy, effectiveness, and efficiency]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (NSCLC, adjuvant) – 2nd Addendum to Project A24-73]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polihexanide (Acanthamoeba keratitis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isavuconazole (mucormycosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isavuconazole (aspergillosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (NSCLC, adjuvant) – Addendum to Project A24-73]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Addendum to Project A24-71]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Capivasertib (breast cancer) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (TNBC, neoadjuvant and adjuvant) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Binimetinib and encorafenib (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (urothelial cancer, first line) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial cancer, first line) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Lorviqua (ALK+ NSCLC)]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Velexbru (primary CNS b-cell lymphoma)]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Padcev (urothelial cancer)]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Nubeqa (Prostate Cancer - mCSPC)]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Crysvita (XLH - x-linked hypophosphatemia)]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Altuviiio lyophilized powder solution for IV injection]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Yervoy (renal cell carcinoma - RCC)]
2024     Center for Drug Evaluation (CDE) [HTA Rapid report-Yervoy (malignant pleural mesothelioma - MPM)]
2024     Center for Drug Evaluation (CDE) [Health Technology Assessment Report : Opdivo (ESCC - first-line treatment)
2024     Center for Drug Evaluation (CDE) [HTA for Medical Device: Metallic biliary stents (Rapid HTA report)]
2024     Center for Drug Evaluation (CDE) [Health Technology Assessment Report : Opdivo (gastric cancer - GC)]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Percutaneous treatment for moderate to severe mitral valve insufficiency]
2024     Institute for Clinical and Economic Review (ICER) Assessment of barriers to fair access
2024     Institute for Clinical and Economic Review (ICER) Unsupported price increase report: unsupported price increases occurring in 2023
2024     Institute for Clinical and Economic Review (ICER) Managing the challenges of paying for gene therapy: strategies for market action and policy reform
2024     Institute for Clinical and Economic Review (ICER) Tabelecleucel for epstein-barr virus positive post-transplant lymphoproliferative disease: effectiveness and value
2024     Institute for Clinical and Economic Review (ICER) Disease modifying therapies for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM)
2024     Institute for Clinical and Economic Review (ICER) Imetelstat for anemia in myelodysplastic syndrome: effectiveness and value
2024     Institute for Clinical and Economic Review (ICER) Ensifentrine for the treatment of chronic obstructive pulmonary disease: effectiveness and value